MoonLake Immunotherapeutics (MLTX) Stock Score, Valuation & Financial Research
MoonLake Immunotherapeutics is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for MLTX
MoonLake Immunotherapeutics does not currently have a complete Wall Street Score. The stored market price is USD 11.71. These figures are a research snapshot, not a buy or sell recommendation.
What MoonLake Immunotherapeutics does
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Company business and revenue
Research reporting period: 2025-12-31. A research update is not a new financial filing.
How the company makes money
MoonLake Immunotherapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of its lead product candidate, sonelokimab, to address inflammatory skin and joint diseases, with the goal of eventually commercializing the therapy or entering into licensing agreements.
Products and services
- The company's primary product candidate is sonelokimab (SLK), a tri-specific Nanobody designed to inhibit IL-17A and IL-17F for the treatment of inflammatory diseases such as hidradenitis suppurativa (HS) and psoriatic arthritis (PsA).
Brands and product families
- Sonelokimab — The company's lead clinical-stage Nanobody product candidate. Source
Customer types
Healthcare providers and patients with inflammatory skin and joint diseases.
Suppliers, materials and equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials. Source
Business strengths to evaluate
- Proprietary Nanobody technology platform Source
Business risks and research considerations
- Dependence on a single product candidate (sonelokimab) Source
- History of operating losses and expectation of future losses Source
- Risks associated with clinical trial outcomes and regulatory approval Source
Sources: Company research source
Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
MLTX financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 11.71
- Market capitalization:
- 985.16M (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -263.67M
- Free cash flow:
- USD -196.04M
- Cash:
- USD 477.91M
- Total debt:
- USD 101.53M
- EPS:
- USD -3.85
What stands out
- Free cash flow is USD -196.04M, negative for the stored period.
- The balance sheet shows USD 477.91M of cash versus USD 101.53M of total debt, an excess of cash over debt on these two reported measures.
- The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Cash exceeds debt by USD 376.37M using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for MLTX
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can MLTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is MLTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for MLTX to reach sustainable profitability?
- What does the current fundamental change risk warning mean for the reliability or interpretation of MLTX's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-05.
Research-input completeness: 73% of the scoring inputs required for this public page are currently available.
How to research MLTX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.